Trial watch: a boost for GSK's first-in-class heart drug?
D050197:Atherosclerosis / Q000188:drug therapy*; D001547:Benzaldehydes / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D006801:Humans; D015201:Meta-Analysis as Topic; D010091:Oximes / Q000627:therapeutic use*; D064801:Phospholipase A2 Inhibitors; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
D001547:Benzaldehydes; D010091:Oximes; D064801:Phospholipase A2 Inhibitors; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides